Osuna-Gómez, R.; López-Pardo, J.; Mulet, M.; Nomdedéu, J.; Cantó, E.; Ortin, R.; Cayuela, Á.S.; Ortiz, M.À.; Guinart-Cuadra, A.; Vidal, S.
Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics 2025, 17, 1278.
https://doi.org/10.3390/pharmaceutics17101278
AMA Style
Osuna-Gómez R, López-Pardo J, Mulet M, Nomdedéu J, Cantó E, Ortin R, Cayuela ÁS, Ortiz MÀ, Guinart-Cuadra A, Vidal S.
Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10):1278.
https://doi.org/10.3390/pharmaceutics17101278
Chicago/Turabian Style
Osuna-Gómez, Rubén, Jordi López-Pardo, Maria Mulet, Josep Nomdedéu, Elisabet Cantó, Rosa Ortin, Ángela Sánchez Cayuela, Ma Àngels Ortiz, Albert Guinart-Cuadra, and Silvia Vidal.
2025. "Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma" Pharmaceutics 17, no. 10: 1278.
https://doi.org/10.3390/pharmaceutics17101278
APA Style
Osuna-Gómez, R., López-Pardo, J., Mulet, M., Nomdedéu, J., Cantó, E., Ortin, R., Cayuela, Á. S., Ortiz, M. À., Guinart-Cuadra, A., & Vidal, S.
(2025). Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics, 17(10), 1278.
https://doi.org/10.3390/pharmaceutics17101278
